UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chronic myeloid leukaemia (CML) in chronic phase. To test this possibility 587 patients with CML in chronic phase were randomly allocated to receive lymphoblastoid cell-line interferon-alpha n1 (IFN-alpha, n = 293) or chemotherapy with busulphan or hydroxyurea (no IFN-alpha, n = 294) as maintenance after initial induction treatment with cytotoxic drugs. There was a significant survival benefit for patients in the IFN-alpha arm when analysed on the basis of intention to treat (2p = 0.0009). The median survival for those allocated IFN-alpha was 61 months and no IFN-alpha was 41 months. Out of 269 patients with Philadelphia-positive CML in the IFN-alpha arm with at least 6 months follow-up, 211 were evaluable for haematological response: 145 (68%) achieved good responses (A+ or A type), 37 (18%) had partial responses (B type) and 29 (14%) had poor responses (C type). Patients with types A and B responses had a better survival than those in the no IFN-alpha arm; patients with type C responses had survival equivalent to the no IFN-alpha arm. Of these 269 patients, 26 of whom had not started IFN-alpha, 59 (22%) achieved a significant degree of cytogenetic response but 210 (78%) did not have a response. Cytogenetic responders survived significantly longer than non-responders and even non-responders survived longer than patients in the no IFN-alpha arm. Since cytogenetic non-responders had worse than average prognostic features, they may also benefit from IFN-alpha therapy. We conclude that treatment with IFN-alpha prolongs the survival of patients with CML; benefits of IFN-alpha are not confined to cytogenetic responders but may extend to most, if not all patients receiving IFN-alpha treatment; and cytogenetic response to IFN-alpha treatment identifies patients with a relatively good prognosis.

[1]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[2]  B. Kennedy,et al.  Hydroxyurea therapy in chronic myelogenous leukemia , 1972, Cancer.

[3]  T. Lion.  Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. The European Investigators on Chronic Myeloid Leukemia Group. , 1994, Bone marrow transplantation.

[4]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[5]  E. Wiltshaw,et al.  Remission Induction in Chronic Granulocytic Leukaemia using Intermittent High‐Dose Busulphan , 1978, British journal of haematology.

[6]  Clinical investigation of human alpha interferon in chronic myelogenous leukemia. , 1987 .

[7]  A. Baikie,et al.  Chronic Granulocytic Leukaemia with Ph1 Negative Cells in Bone Marrow and a Ten Year Remission after Busulphan Hypoplasia , 1972, British journal of haematology.

[8]  F. Grignani,et al.  Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. , 1988, Blood.

[9]  M. Cazzola,et al.  Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph‐negative peripheral stem cells , 1994, British journal of haematology.

[10]  N. Niederle,et al.  Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients. , 1991, European journal of cancer.

[11]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[12]  D. Galton.  Myleran in chronic myeloid leukaemia; results of treatment. , 1953, Lancet.

[13]  A. Billiau.  Standardization of interferons , 1984 .

[14]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[15]  Y. Kodera,et al.  Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. , 1994, Bone marrow transplantation.

[16]  R. Chaganti,et al.  Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). , 1979, Blood.

[17]  Nathan Mantel,et al.  Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .

[18]  R. Gray,et al.  Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non‐cirrhotic portal hypertension. RESULTS FROM MRC CML II TRIAL COMPARING BUSULPHAN WITH BUSULPHAN AND THIOGUANINE , 1991, British journal of haematology.

[19]  A. Cross.  Busulphan and bone marrow depression. , 1969, British medical journal.

[20]  F. Mandelli,et al.  The Role of Interferon in the Treatment of Chronic Myelogenous Leukemia: Results and Prospects , 1992 .